Genomic Profiling, Risk Stratification, and Post-Transformation Treatment Outcomes in Patients with Transformed Small-Cell Lung Cancer: A Multicenter Analysis.
Aug 2026· Lung Cancer· Vol 220, pp.
109566
· 0 citations· 25 references
Medicine
TL;DR
Age, RB1/NTRK1 mutation, and secondary T790M mutation were identified as independent risk factors and integrated into a predictive model with high accuracy and establish a clinically applicable model for early prediction and risk stratification of SCLC transformation.
Abstract
Background
Transformed small-cell lung cancer (T-SCLC) is an increasingly recognized resistance mechanism in EGFR-mutant lung adenocarcinoma. This study aimed to identify early predictors of histologic transformation and evaluate post-transformation treatment outcomes.
Methods
We retrospectively collected 163 T-SCLC patients from five Chinese centers. Next-generation sequencing was performed on 60 EGFR-mutant patients, including 47 paired primary-transformed samples. Integrated genomic and clinical analyses were conducted to delineate molecular features and survival outcomes.
Results
Among 150 EGFR-mutant patients, the median time to SCLC transformation was 25.8 months and median post-transformation overall survival (OS) was 14.2 months. Clinical and survival data for the 13 EGFR wild-type patients are reported descriptively given the limited sample size. Among 108 treatment-evaluable patients, first-line EGFR-TKI plus chemotherapy, chemotherapy alone, and immune checkpoint inhibitors (ICIs) plus chemotherapy yielded median progression-free survival (PFS) of 6.2, 5.30, and 4.07 months (P = 0.041) and median OS of 21.2, 27.6, and 13.6 months (P = 0.193). In later-line therapy, taxane-based regimens achieved a median PFS of 6.93 months, outperforming camptothecin-based (1.13 months) and other regimens (1.90 months; P = 0.049). High evolutionary diversity was associated with shorter post-transformation OS (6.77 vs. 11.10 months), with restricted cubic spline analysis showing a nonsignificant trend toward a nonlinear association (P = 0.055).Age, RB1/NTRK1 mutation, and secondary T790M mutation were identified as independent risk factors and integrated into a predictive model with high accuracy.
Conclusions
This study establishes a clinically applicable model for early prediction and risk stratification of SCLC transformation. Taxane-based regimens emerge as a promising later-line therapeutic option for T-SCLC.
The survival outcomes observed in this cohort were generally consistent with previously published real-world data in EGFR-mutant metastatic NSCLC, and ECOG performance status and bone metastasis were significantly associated with OS, while associations involving histopathological subtype and uncommon EGFR mutations sho...
A. Koçanoğlu, O. Ünsal, F. Kuş et al.· Journal of Clinical Medicine· 0 citations
Lung adenocarcinoma (LAD) is the most common non-small cell lung cancer subtype, with frequent epidermal growth factor receptor (EGFR) mutations in Asians. First-line tyrosine kinase inhibitors (TKIs) improves survival but resistance is inevitable, leading to disease progression and even death. We aimed to develo...
Wen-Jian Tang, Jia-Wei Feng, Yuan Kang et al.· BMC Pulmonary Medicine· 0 citations
INTRODUCTION
Human epidermal growth factor receptor 2 (HER2/ERBB2) mutated non-small cell lung cancer (NSCLC) is associated with poor prognosis and limited treatment options.
METHODS
This retrospective cohort study used electronic health records from US academic and community cancer centers to describe characteristic...
Xiu-Ning Le, C. Chouaid, F. López-Ríos et al.· Lung Cancer· 0 citations
Although EGFR inhibitors are highly effective for treating EGFR-mutant lung adenocarcinomas (EGFR+ LUADs), resistance inevitably emerges, with histologic transformation to small cell lung cancer (SCLC) representing a particularly aggressive mechanism. Our prospective trial enrolled patients with EGFR+ LUAD at high risk...
L. Morrill Gavarró, Monica F. Chen, Á. Quintanal-Villalonga et al.· Science Translational Medici...· 0 citations
51
Background:
Broad genomic profiling (BGP) is recommended for all patients with metastatic non-squamous NSCLC to guide targeted therapy (TT) selection. As actionable alterations and matched therapies continue to expand, BGP may identify a broader group of patients eligible for TT and consequently improve pati...
Si-Da Huang, John Rothen, Jessica B. Long et al.· JCO Oncology Practice· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.